RLMD
Relmada TherapeuticsDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Operating peers and competitors
Source-backed product markets and frozen research comparisons. Valuation comparators remain in the existing peer table.
Loading market evidence...
Research comparisons do not establish forecast usefulness or trading returns.
Compare shared product markets
Membership only; no portfolio weights or estimated losses.
+
Peers tracked
10
U.S. public peers
Grade Position
In line
vs peer average
RLMD vs peer average
45/100
RLMD vs. peer average (D vs. D)
Grade spread
A 1 · B 1 · C 1 · D 4 · F 3
Graded peers loaded
Coverage
10 graded
100% of tracked
Peer overview
CAPR is the first available peer comparator.
Similarly sized clinical-stage biotech; useful for comparing milestone-driven volatility, but its programs are not a direct NDV-01 valuation benchmark.
✓Peer source comes from the stored AI memo or peer model
✓Grades and factor rows use RankAlpha API data when available
✓Missing peer scores remain blank instead of being estimated
✓Side-by-side comparison keeps the data contract visible
RLMD
Relmada Therapeutics
CAPR
Capricor Therapeutics
Grade
D
F
Momentum
9
4
Value
41
41
Sentiment
50
19
Setup Bias
Net —
-
Market Cap
-
-
Posture
Defensive
Defensive
Grade position vs CAPR
RLMD / CAPR
Grade Position
In line
RLMD vs. peer average (D vs. D)
45/100
Momentum
9
RLMDValue
41
RLMDSentiment
50
RLMDRotation landscape
Peers ranked by the order returned from the peer source, with grades from the API.
Rank
Ticker
Company
Grade
Grade score
vs RLMD
CAPR is the first peer returned for this comparison set.